Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
1.490
+0.030 (2.05%)
At close: Dec 12, 2025, 4:00 PM EST
1.480
-0.010 (-0.67%)
After-hours: Dec 12, 2025, 7:30 PM EST
Alector Revenue
Alector had revenue of $3.26M in the quarter ending September 30, 2025, a decrease of -78.75%. This brings the company's revenue in the last twelve months to $69.05M, up 12.26% year-over-year. In the year 2024, Alector had annual revenue of $100.56M with 3.60% growth.
Revenue (ttm)
$69.05M
Revenue Growth
+12.26%
P/S Ratio
2.16
Revenue / Employee
$290,118
Employees
238
Market Cap
162.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
| Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
| Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
| Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
| Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
| Dec 31, 2019 | 21.22M | -6.46M | -23.33% |
| Dec 31, 2018 | 27.68M | 23.94M | 641.02% |
| Dec 31, 2017 | 3.74M | 3.32M | 797.84% |
| Dec 31, 2016 | 416.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALEC News
- 1 day ago - Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer - GlobeNewsWire
- 5 days ago - Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript - Seeking Alpha
- 12 days ago - Alector to Participate in the Bank of America CNS Therapeutics Conference - GlobeNewsWire
- 17 days ago - ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 5 weeks ago - Alector Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Benzinga
- 7 weeks ago - Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic - GlobeNewsWire
- 7 weeks ago - Alector shares plunge after dementia drug fails to slow disease progression - Reuters